Canaccord Genuity Maintains a 'Hold' on Perrigo (PRGO); Consumer is Key to Upside in Stock Now
Tweet
Share
E-mailGet Alerts PRGO Hot Sheet
Price: $14.25 +4.01%
Rating Summary:
12 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
12 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on Perrigo Co. (NASDAQ: PRGO) price target of $105.00.
Analyst, Randall Stanicky, said, "PRGO put up a solid fiscal Q2 result off the back of another strong Generic Rx quarter and against a well-advertised weak cough-and-cold season. We exit the quarter more comfortable with the near-term outlook and what will likely be viewed as less risk to numbers from here. We did hear some concern today around (1) valuation in the context of greater Rx contribution (lower comp value) and (2) confidence in Consumer Health outlook given what is perhaps some unexpected competitive benefit. While fair, though not new, Perrigo is also benefiting from its diversified footprint with a better F2H launch outlook ahead. Bottom line, we think upside in Consumer Health is key to the stock from here, which is where our focus lies; remain HOLD for now."
For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.
Shares of Perrigo Co. closed at $95.26 yesterday.
Analyst, Randall Stanicky, said, "PRGO put up a solid fiscal Q2 result off the back of another strong Generic Rx quarter and against a well-advertised weak cough-and-cold season. We exit the quarter more comfortable with the near-term outlook and what will likely be viewed as less risk to numbers from here. We did hear some concern today around (1) valuation in the context of greater Rx contribution (lower comp value) and (2) confidence in Consumer Health outlook given what is perhaps some unexpected competitive benefit. While fair, though not new, Perrigo is also benefiting from its diversified footprint with a better F2H launch outlook ahead. Bottom line, we think upside in Consumer Health is key to the stock from here, which is where our focus lies; remain HOLD for now."
For an analyst ratings summary and ratings history on Perrigo Co. click here. For more ratings news on Perrigo Co. click here.
Shares of Perrigo Co. closed at $95.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
